...That's great. Thanks, Shannon, and good morning, everybody, and thank you all for joining us today. The past several months have certainly been a busy but more importantly, a very exciting time for fulcrum marked by significant progress with our lead program Poser for the treatment of sickle cell disease, which is an inherited blood disorder with a high unmet need afflicting approximately 100,000 people in the US and approximately 7.7 million people worldwide. There is an ever increasing need for better treatment options for sickle cell disease patients who face not only an impaired quality of life due to chronic pain, fatigue, and acute complications like vaso-occlusive crisis, but also very high rates of mortality. Patients with sickle cell disease face a greater than twenty-year reduction in life expectancy with a mortality rate that is nine times higher than the general population. And so, as we continue on our journey to find better treatment options for these patients, we were very...
